NeoTherma VectRx - Clinical Stage Medical Device

We are integrating our novel application of electromagnetic field physics with cutting-edge MRI thermographic imaging and computational simulation in a medical device that promises to be a disruptive adjuvant treatment for deep solid tumors, initially targeting pancreatic cancer. Evidence shows that modestly raising the temperature in the tumor microenvironment (from the normal core temperature of 37°C to 41-43°C) significantly increases the effectiveness of radio-, chemo- and immunotherapies with minimal side effects.

Peer-reviewed clinical evidence from a number of centers around the world demonstrates that RF thermal therapy works by increasing blood perfusion in the tumor micro-environment (allowing drugs to better penetrate), reversing radiation treatment-resistant hypoxia (increasing intratumoral reactive oxygen) and promoting a therapeutic immune response similar and likely additive to immune checkpoint inhibition (increasing immunogenic tumor cell surface protein expression). Our lead target, unresectable pancreatic adenocarcinoma, is statistically the deadliest of all solid tumors, and the technology may be equally applicable to a wide range of solid tumors.

Importantly, mild hyperthermia (41-43°C) has been demonstrated to initiate an effective immune response on its own. Thus, it may be an even better complement to immunotherapy as radiotherapy and chemotherapy may suppress the main actors of the immune system.